Descrizione del progetto
Proteine terapeutiche basate su vescicole
Molti farmaci emergenti sono proteine. La loro efficacia dipende tuttavia da una serie di fattori fisici e chimici, il che ha portato all’uso di polimeri come agenti stabilizzanti. Il progetto ProDelivery, finanziato dall’UE, propone di sviluppare una piattaforma chimica per la sintesi di vescicole polimeriche incapsulate con proteine. I ricercatori studieranno le relazioni tra struttura e attività delle vescicole e il loro impatto sulla stabilità delle proteine e sul rilascio nei bersagli biologici. La piattaforma generata è altamente versatile e ha il potenziale per superare gli attuali limiti negli studi sistematici di proteine terapeutiche basate su polimeri, principalmente a causa del costo elevato.
Obiettivo
The delivery of therapeutic protein drugs in biological environments is hampered by their relative sensitivity to a broad range of physical and chemical factors. To address this loss in therapeutic efficacy, chemical formulations using polymers as stabilising agents have been proposed. Unfortunately, systematic studies of these formulations are often limited in scope owing to the relatively high cost of protein therapeutics as well as restrictions on the types of chemical transformations that can be performed without loss of protein activity. Hosted within Prof. Molly Stevens' labs at Imperial College London (www.stevensgroup.org recognised by >25 major awards), the overall goal of this proposal is therefore to develop a versatile chemical synthetic platform enabling the efficient synthesis of protein encapsulated polymeric vesicles. This will be achieved by exploiting low volume, high throughput polymer chemistry to allow for a cost and time efficient study of vesicle structure-activity relationships in the context of protein stabilisation and efficacious delivery of proteins to biological targets. The proposed combinatorial approach is highly versatile and can, in principle, be applied for the study of a broad range of proteins or other biologically relevant therapeutics. The versatility and translation potential of this project will be fully evaluated within the excellent infrastructure available within the Stevens Group.
Campo scientifico
Programma(i)
Argomento(i)
Meccanismo di finanziamento
MSCA-IF-EF-ST - Standard EFCoordinatore
SW7 2AZ LONDON
Regno Unito